Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review

V Kumar, P Singh, SK Gupta, V Ali, M Verma - Molecular and Cellular …, 2022 - Springer
Abstract Imatinib, nilotinib, dasatinib, bosutinib, ponatinib, and asciminib are FDA-approved
tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML), each of which has a …
被引用次数：28 相关文章

Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review.

V Kumar, P Singh, SK Gupta, V Ali… - Molecular & Cellular …, 2022 - search.ebscohost.com
Abstract Imatinib, nilotinib, dasatinib, bosutinib, ponatinib, and asciminib are FDA-approved
tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML), each of which has a …

Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review

V Kumar, P Singh, SK Gupta, V Ali… - Molecular and …, 2022 - pubmed.ncbi.nlm.nih.gov
Imatinib, nilotinib, dasatinib, bosutinib, ponatinib, and asciminib are FDA-approved tyrosine
kinase inhibitors (TKIs) for chronic myeloid leukemia (CML), each of which has a specific …

Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review.

V Kumar, P Singh, SK Gupta, V Ali… - Molecular and Cellular …, 2022 - go.gale.com
Imatinib, nilotinib, dasatinib, bosutinib, ponatinib, and asciminib are FDA-approved tyrosine
kinase inhibitors (TKIs) for chronic myeloid leukemia (CML), each of which has a specific …

Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review

V Kumar, P Singh, SK Gupta, V Ali, M Verma - 2022 - kr.cup.edu.in
Imatinib, nilotinib, dasatinib, bosutinib, ponatinib, and asciminib are FDA-approved tyrosine
kinase inhibitors (TKIs) for chronic myeloid leukemia (CML), each of which has a specific …
[PDF] researchgate.net

[PDF][PDF] Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review

V Kumar, P Singh, SK Gupta, V Ali, M Verma - researchgate.net
Abstract Imatinib, nilotinib, dasatinib, bosutinib, ponatinib, and asciminib are FDA-approved
tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML), each of which has a …

Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review.

V Kumar, P Singh, SK Gupta, V Ali… - Molecular and Cellular …, 2022 - europepmc.org
Imatinib, nilotinib, dasatinib, bosutinib, ponatinib, and asciminib are FDA-approved tyrosine
kinase inhibitors (TKIs) for chronic myeloid leukemia (CML), each of which has a specific …
[PDF] researchgate.net

[PDF][PDF] Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review

V Kumar, P Singh, SK Gupta, V Ali, M Verma - researchgate.net
Abstract Imatinib, nilotinib, dasatinib, bosutinib, ponatinib, and asciminib are FDA-approved
tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML), each of which has a …